Sun Nian-Kang, Huang Shang-Lang, Chang Ting-Chang, Chao Chuck C-K
Department of Biochemistry and Molecular Biology, College of Medicine, Chang Gung University, Taoyuan, Taiwan, Republic of China.
Division of Biomedical Sciences, Chang Gung University of Science and Technology, Taoyuan, Taiwan, Republic of China.
J Cell Physiol. 2018 Mar;233(3):2489-2501. doi: 10.1002/jcp.26125. Epub 2017 Aug 30.
We report here that toll-like receptor 4 (TLR4) and ABCB1 are upregulated in SKOV3 ovarian carcinoma cells that acquired resistance to the anticancer drug taxol. Silencing of TLR4 using short-hairpin RNA sensitized taxol-resistant SKOV3 cells to taxol (4.6 fold), whereas ectopic expression of TLR4 in parental, taxol-sensitive SKOV3 cells or TLR4-null HEK293 cells induced taxol resistance (∼2 fold). A sub-lethal dose of taxol induced ABCB1 protein expression in taxol-resistant SKOV3 cells. Inactivation of TLR4 using chemical inhibitors (CLI-095 and AO-I) downregulated ABCB1 protein expression and enhanced the cytotoxic activity of taxol in taxol-resistant SKOV3 cells. While the sensitization effect of TLR4 inactivation was also detected in TOV21G ovarian cancer cells, which express moderate level of TLR4, ectopic expression of ABCB1 prevented the sensitization effect in these cells. Notably, the NFκB pathway was significantly activated by taxol, and inhibition of this pathway suppressed TLR4-regulated ABCB1 expression. Furthermore, taxol-induced NFκB signaling was reduced following TLR4 silencing in taxol-resistant SKOV3 cells. Consistent with these results, ectopic expression of TLR4 in taxol-sensitive SKOV3 cells enhanced ABCB1 expression and conferred resistance to taxol. The protective effect of exogenous TLR4 expression against taxol was reduced by treatment with NFκB inhibitor in these cells. These results demonstrate that taxol activates the TLR4-NFκB pathway which in turn induces ABCB1 gene expression. This cellular pathway thus represents a novel target to limit resistance to taxol in ovarian cancer cells.
我们在此报告,在对抗癌药物紫杉醇产生耐药性的SKOV3卵巢癌细胞中,Toll样受体4(TLR4)和ABCB1上调。使用短发夹RNA沉默TLR4可使耐紫杉醇的SKOV3细胞对紫杉醇敏感(4.6倍),而在亲本的、对紫杉醇敏感的SKOV3细胞或TLR4基因缺失的HEK293细胞中异位表达TLR4则诱导紫杉醇耐药(约2倍)。亚致死剂量的紫杉醇可诱导耐紫杉醇的SKOV3细胞中ABCB1蛋白表达。使用化学抑制剂(CLI-095和AO-I)使TLR4失活可下调ABCB1蛋白表达,并增强紫杉醇对耐紫杉醇的SKOV3细胞的细胞毒活性。虽然在表达中等水平TLR4的TOV21G卵巢癌细胞中也检测到了TLR4失活的致敏作用,但ABCB1的异位表达可阻止这些细胞中的致敏作用。值得注意的是,紫杉醇可显著激活NFκB通路,抑制该通路可抑制TLR4调节的ABCB1表达。此外,在耐紫杉醇的SKOV3细胞中沉默TLR4后,紫杉醇诱导的NFκB信号传导减弱。与这些结果一致,在对紫杉醇敏感的SKOV3细胞中异位表达TLR4可增强ABCB1表达并赋予对紫杉醇的耐药性。在这些细胞中用NFκB抑制剂处理可降低外源性TLR4表达对紫杉醇的保护作用。这些结果表明,紫杉醇激活TLR4-NFκB通路,进而诱导ABCB1基因表达。因此,这条细胞通路代表了限制卵巢癌细胞对紫杉醇耐药性的一个新靶点。